National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Merkel Cell Carcinoma Treatment (PDQ®)
Patient Version   Health Professional Version   En español   Last Modified: 12/13/2007



Purpose of This PDQ Summary






General Information






Cellular Classification






Stage Information






Stage I Merkel Cell Carcinoma






Stage II Merkel Cell Carcinoma






Stage III Merkel Cell Carcinoma






Recurrent Merkel Cell Carcinoma






Get More Information From NCI






Changes to This Summary (12/13/2007)






More Information



Page Options
Print This Page
Print Entire Document
View Entire Document
E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
Quit Smoking Today
NCI Highlights
Report to Nation Finds Declines in Cancer Incidence, Death Rates

High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

The Nation's Investment in Cancer Research FY 2009

Past Highlights
Stage III Merkel Cell Carcinoma

Current Clinical Trials

Note: Some citations in the text of this section are followed by a level of evidence. The PDQ editorial boards use a formal ranking system to help the reader judge the strength of evidence linked to the reported results of a therapeutic strategy. (Refer to the PDQ summary on Levels of Evidence for more information.)

Chemotherapy is the treatment most often used for patients with stage III Merkel cell carcinoma (MCC).[1-5][Level of evidence: 3iiiDiv] Because of morphologic and immunohistochemical similarities, the regimens employed are similar to those used for patients with small cell lung cancer. (See the PDQ summary on Small Cell Lung Cancer Treatment for chemotherapeutic options.) Cyclophosphamide, doxorubicin, and vincristine and etoposide plus cisplatin are the most commonly used regimens. MCC often responds to chemotherapy initially, but the response is usually short-lived and the impact of chemotherapy on survival is uncertain.[1-5]

Current Clinical Trials

Check for U.S. clinical trials from NCI's PDQ Cancer Clinical Trials Registry that are now accepting patients with stage III neuroendocrine carcinoma of the skin. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.

General information about clinical trials is also available from the NCI Web site.

References

  1. Haag ML, Glass LF, Fenske NA: Merkel cell carcinoma. Diagnosis and treatment. Dermatol Surg 21 (8): 669-83, 1995.  [PUBMED Abstract]

  2. Ratner D, Nelson BR, Brown MD, et al.: Merkel cell carcinoma. J Am Acad Dermatol 29 (2 Pt 1): 143-56, 1993.  [PUBMED Abstract]

  3. Tai PT, Yu E, Winquist E, et al.: Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: case series and review of 204 cases. J Clin Oncol 18 (12): 2493-9, 2000.  [PUBMED Abstract]

  4. Feun LG, Savaraj N, Legha SS, et al.: Chemotherapy for metastatic Merkel cell carcinoma. Review of the M.D. Anderson Hospital's experience. Cancer 62 (4): 683-5, 1988.  [PUBMED Abstract]

  5. Voog E, Biron P, Martin JP, et al.: Chemotherapy for patients with locally advanced or metastatic Merkel cell carcinoma. Cancer 85 (12): 2589-95, 1999.  [PUBMED Abstract]

Back to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov